EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment

Koki Takagi, Ariunbuyan Sukhbaatar iD, Yohei Inaba, Shiro Mori, Tetsuya Kodama iD

Cancer Science · 2024

DOI: 10.1111/cas.16369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Koki Takagi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Radioimmunotherapy, Drug Delivery Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Suzuken Memorial Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of radiotherapy and immunotherapy is a promising approach that has been shown in clinical trials to improve significantly survival and response rates compared with monotherapy against solid tumor. Since anti‐CTLA‐4 antibodies block immunosuppressive signals mainly in the lymph nodes (LNs), efficient drug delivery to the lymphatic system is desirable. However, the immune checkpoint inhibitors, especially anti‐CTLA‐4 are currently administered intravenously (i.v.), resulting in limited efficacy in controlling solid tumor and inhibiting metastases, and the method of administration has not been optimized. Here, we show that a combination of local radiotherapy and administration of anti‐CTLA‐4 antibodies using a lymphatic drug delivery system (LDDS) suppresses solid tumor and metastases. We compared the efficacy of LDDS‐based immunotherapy or radioimmunotherapy with i.v. administration in a solid‐tumor model created by subcutaneous inoculation into LN‐swollen mice with osteosarcoma cells. Tumor‐bearing mice were divided into various groups (no treatment, immunotherapy [i.v. or LDDS], radiotherapy, and radioimmunotherapy [i.v. or LDDS]) and were observed for 28 days. Immunotherapy was administered with a cumulative dose of 10 mg/kg of anti‐CTLA‐4 monoclonal antibody, and radiotherapy was administered with a cumulative 8 Gy of fractionated X‐ray irradiation. For immunotherapy alone, LDDS provided slight tumor growth inhibition but did not inhibit distant metastasis. For radioimmunotherapy, however, tumor growth was delayed and distant metastasis was suppressed compared with radiotherapy alone. In particular, the LDDS group achieved a high tumor‐suppressive effect with T cell‐mediated immune activity, indicating the efficacy of LDDS in radioimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CTLA-4 AntigenRadioimmunotherapyDrug Delivery SystemsAnimalsMiceCell Line, TumorHumansAntibodies, MonoclonalLymph NodesImmunotherapyImmune Checkpoint InhibitorsOsteosarcomaFemaleCombined Modality TherapyBone NeoplasmsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

anti‐CTLA‐4 antibodyimmune checkpoint inhibitorimmune‐related adverse eventslymphatic drug delivery systemradiotherapy

Substanzen

CTLA-4 AntigenAntibodies, MonoclonalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Laboratory of Biomedical Engineering for Cancer, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan.
  • Division of Oral and Maxillofacial Oncology and Surgical Sciences, Graduate School of Dentistry, Tohoku University, Sendai, Miyagi, Japan.
  • Biomedical Engineering Cancer Research Center, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan.
  • Department of Radiological Technology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Department of Radiation Disaster Medicine, International Research Institute of Disaster Science, Tohoku University, Sendai, Miyagi, Japan.

ORCID-Profile: Ariunbuyan Sukhbaatar, Tetsuya Kodama

Förderung

  • Japan Society for the Promotion of Science
  • Suzuken Memorial Foundation

Zitieren

APA

Takagi, K., Sukhbaatar, A., Inaba, Y., Mori, S., & Kodama, T. (2024). A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment. Cancer Science. https://doi.org/10.1111/cas.16369

Vancouver

Takagi K, Sukhbaatar A, Inaba Y, Mori S, Kodama T. A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment. Cancer Science. 2024. doi:10.1111/cas.16369

BibTeX
@article{Takagi2024,
  author = {Takagi, Koki and Sukhbaatar, Ariunbuyan and Inaba, Yohei and Mori, Shiro and Kodama, Tetsuya},
  title = {A combination of lymphatic drug delivery of anti‐ CTLA ‐4 antibody and local radiotherapy for solid‐tumor treatment},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16369}
}
Kostenlos starten →